Lipid Sciences Begins HDL Therapy Trial

Lipid Sciences has enrolled all patients in its trial to demonstrate the safety and efficacy of the company’s HDL Selective Delipidation process.

Lewis Meyer, Lipid Sciences’ president and CEO, said the FDA-approved protocol allowed the company to enroll a maximum of 30 patients based on a dropout rate of approximately 33 percent. The trial’s 92 percent retention rate has allowed the company to gather sufficient data from 28 patients.

Trial participants will complete their scheduled plasma collection and re-infusion treatments by the end of January 2008.